KROS - Keros issued U.S. patent for use of therapeutic proteins in treatment of musculoskeletal disorders

Keros Therapeutics (KROS) announces the issuance of U.S. patent for the use of therapeutic proteins in treatment of musculoskeletal disorders.The United States Patent and Trademark Office (“USPTO”) has issued the company U.S. Patent No. 11,013,785.The patent contains 20 claims and expires no earlier than November 2037, the company said.Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia.The company had announced results from a preclinical study of KER-012 on pulmonary and cardiac dysfunction in an established rodent model of pulmonary arterial hypertension ((PAH)), earlier this month.

For further details see:

Keros issued U.S. patent for use of therapeutic proteins in treatment of musculoskeletal disorders